Brussels, 25/01/2001 (Agence Europe) - Two new anti-malaria vaccines, issued from European research, have entered in to the clinical trails phase. They are both aimed at producing an immune response in children, which form the most vulnerable group from the tropical infectious disease.
The first vaccine, named "MSP-3"is the fruit of research supported by the EU and coordinated by Pierre Druilhe from the Pasteur Institute in Paris (France), with scientists from several countries: Brazil,...